Differential Immunohistological features of inflammatory myopathies and dysferlinopathy

Journal of Korean Medical Science

Volumn 24, Issue 6, 2009, Pages 1015-1023

  Choi, Jae Hwan ^a   Park, Yeong Eun ^a   Kim, Sung Il ^a   Kim, Jeong Il ^a   Lee, Chang Hoon ^a   Park, Kyu Hyun ^a   Kim, Dae Seong ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Complement membrane attack complex; Dermatomyositis; Major histocompatibility complex class I; Muscular dystrophies; Polymyositis

Indexed keywords

DYSF PROTEIN, HUMAN; MEMBRANE PROTEIN; MUSCLE PROTEIN;

ADULT; AGED; ARTICLE; CYTOLOGY; DERMATOMYOSITIS; FEMALE; GENE; GENETICS; HUMAN; IMMUNOLOGY; LIMB GIRDLE MUSCULAR DYSTROPHY; MALE; MIDDLE AGED; MYOSITIS; PATHOLOGY; POLYMYOSITIS; SKELETAL MUSCLE; T LYMPHOCYTE;

ADULT; AGED; DERMATOMYOSITIS; FEMALE; GENES, MHC CLASS I; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MYOSITIS; POLYMYOSITIS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 75349083088     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.6.1015     Document Type: Article

References (30)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
2. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-82.
3. Briani C, Doria A, Sarzi-Puttini P, Dalakas MC. Update on idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 161-70.
4. Gallardo E, Rojas-Garcia R, de Luna N, Pou A, Brown RH Jr, Illa I. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001; 57: 2136-8.
5. Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Ben Hamida M, Bohlega S, Culper EJ, Amato AA, Bossie K, Oeltjen J, Bejaoui K, McKenna-Yasek D, Hosler BA, Schurr E, Arahata K, de Jong PJ, Brown RH Jr. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nature Genet 1998; 20: 31-6.
6. Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, Walsh J, Johnson MA, Bashir R, Britton S, Keers S, Argov Z, Mahjneh I, Fougerousse F, Beckmann JS, Bushby KM. Dysferlin is a plasma membrane protein and is expressed early in human development. HumMol Genet 1999; 8: 855-61.
7. Kim DS, Park KH, Nam SO, Lee CH, Park KJ. Significance of immunohistochemical study in patients with muscular dystrophy. J Korean Neurol Assoc 2004; 22: 613-22.
8. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004; 17: 561-7.
9. Rowe DJ, Isenberg DA, McDougall J, Beverley PC. Characterization of polymyositis infiltrates using monoclonal antibodies to human leucocyte antigens. Clin Exp Immunol 1981; 45: 290-8.
10. Rowe D, Isenberg DA, Beverley PC. Monoclonal antibodies to human leucocyte antigens in polymyositis and muscular dystrophy. Clin Exp Immunol 1983; 54: 327-36.
11. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986; 17: 704-21.
12. Vianna MA, Borges CT, Borba EF, Caleiro MT, Bonfa E, Marie SK. Myositis in mixed connective tissue disease: a unique syndrome characterized by immunohistopathologic elements of both polymyositis and dermatomyositis. Arq Neuropsiquiatr 2004; 62: 923-34.
13. Brunn A, Schroder R, Deckert M. The inflammatory reaction pattern distinguishes primary dysferlinopathies from idiopathic inflammatory myopathies: an important role for the membrane attack complex. Acta Neuropathol 2006; 112: 325-32.
14. Bittner RE, Anderson LV, Burkhardt E, Bashir R, Vafiadaki E, Ivanova S, Raffelsberger T, Maerk I, Ho_ger H, Jung M, Karbasiyan M, Storch M, Lassmann H, Moss JA, Davison K, Harrison R, Bushby KM, Reis A. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet 1999; 23: 141-2.
15. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988; 23: 64-72.
16. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20: 224-31.
17. Nyberg P, Wikman AL, Nennesmo I, Lundberg I. Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 2000; 27: 940-8.
18. Civatte M, Schleinitz N, Krammer P, Fernandez C, Guis S, Veit V, Pouget J, Harle@ JR, Pellissier JF, Figarella-Branger D. Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM). Neuropathol Appl Neurobiol 2003; 29: 546-52.
19. van der Pas J, Hengstman GJ, ter Laak HJ, Borm GF, van Engelen BG. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004; 75: 136-9.
20. Bao SS, King NJ, dos Remedios CG. Elevated MHC class I and II antigens in cultured human embryonic myoblasts following stimulation with gamma-interferon. Immunol Cell Biol 1990; 68: 235-41.
21. Michaelis D, Goebels N, Hohlfeld R. Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 1993; 143: 1142-9.
22. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, Danning C, Wada R, Thompson C, Bahtiyar G, Craft J, Hooft Van Huijsduijnen R, Plotz P. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositisspecific autoantibodies. Proc Natl Acad Sci USA 2000; 97: 9209-14.
23. Englund P, Nennesmo I, Klareskog L, Lundberg IE. Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 2002; 46: 1044-55.
24. Englund P, Lindroos E, Nennesmo I, Klareskog L, Lundberg IE. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001; 159: 1263-73.
25. Confalonieri P, Oliva L, Andreetta F, Lorenzoni R, Dassi P, Mariani E, Morandi L, Mora M, Cornelio F, Mantegazza R. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 2003; 142: 130-6.
26. Kostek CA, Dominov JA, Miller JB. Up-regulation of MHC class I expression accompanies but is not required for spontaneous myopathy in dysferlin-deficient SJL/J mice. Am J Pathol 2002; 160: 833-9.
27. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990; 27: 343-56.
28. Kissel JT, Halterman RK, Rammohan KW, Mendell JR. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 1991; 48: 26-30.
29. Sakuta R, Murakami N, Jin Y, Nagai T, Nonaka I, Nishino I. Diagnostic significance of membrane attack complex and vitronectin in childhood dermatomyositis. J Child Neurol 2005; 20: 597-602.
30. Spuler S, Engel AG. Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies. Neurology 1998; 50: 41-6.